CH646793A5 - In-vitro-verfahren zur diagnose von malignen tumoren. - Google Patents
In-vitro-verfahren zur diagnose von malignen tumoren. Download PDFInfo
- Publication number
- CH646793A5 CH646793A5 CH1232978A CH1232978A CH646793A5 CH 646793 A5 CH646793 A5 CH 646793A5 CH 1232978 A CH1232978 A CH 1232978A CH 1232978 A CH1232978 A CH 1232978A CH 646793 A5 CH646793 A5 CH 646793A5
- Authority
- CH
- Switzerland
- Prior art keywords
- solution
- antigen
- test
- migration
- suspension
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 13
- 201000011510 cancer Diseases 0.000 title description 7
- 238000000338 in vitro Methods 0.000 title description 5
- 238000003745 diagnosis Methods 0.000 title description 3
- 239000000243 solution Substances 0.000 description 38
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 32
- 210000000265 leukocyte Anatomy 0.000 description 29
- 238000012360 testing method Methods 0.000 description 26
- 238000013508 migration Methods 0.000 description 22
- 230000005012 migration Effects 0.000 description 22
- 239000000725 suspension Substances 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 20
- 108010074506 Transfer Factor Proteins 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 229920001817 Agar Polymers 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000004080 punching Methods 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000794475 Schistosoma mansoni Calcium-binding protein Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2755363A DE2755363C3 (de) | 1977-12-12 | 1977-12-12 | Testverfahren zur Diagnose von Malignomen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH646793A5 true CH646793A5 (de) | 1984-12-14 |
Family
ID=6025947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1232978A CH646793A5 (de) | 1977-12-12 | 1978-12-01 | In-vitro-verfahren zur diagnose von malignen tumoren. |
Country Status (25)
| Country | Link |
|---|---|
| JP (1) | JPS54100176A (fr) |
| AR (1) | AR220356A1 (fr) |
| AT (1) | AT360178B (fr) |
| AU (1) | AU4234978A (fr) |
| BE (1) | BE872651A (fr) |
| CA (1) | CA1129319A (fr) |
| CH (1) | CH646793A5 (fr) |
| DD (1) | DD139903A5 (fr) |
| DE (1) | DE2755363C3 (fr) |
| DK (1) | DK532678A (fr) |
| ES (2) | ES475905A1 (fr) |
| FI (1) | FI783782A7 (fr) |
| FR (1) | FR2411412A1 (fr) |
| GB (1) | GB2009927B (fr) |
| GR (1) | GR66576B (fr) |
| IL (1) | IL56152A0 (fr) |
| IT (1) | IT1160323B (fr) |
| LU (1) | LU80609A1 (fr) |
| NL (1) | NL7811903A (fr) |
| NO (1) | NO784096L (fr) |
| PL (1) | PL112675B1 (fr) |
| PT (1) | PT68891A (fr) |
| RO (1) | RO75333A (fr) |
| SE (1) | SE432157B (fr) |
| ZA (1) | ZA786908B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436824A (en) * | 1981-06-09 | 1984-03-13 | Ortho Diagnostic Systems, Inc. | Leukocyte migration through antigen containing agaroses for immunocompetence testing |
| JPH0672158B2 (ja) * | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
-
1977
- 1977-12-12 DE DE2755363A patent/DE2755363C3/de not_active Expired
-
1978
- 1978-11-29 SE SE7812313A patent/SE432157B/sv unknown
- 1978-11-29 DK DK532678A patent/DK532678A/da unknown
- 1978-11-29 GR GR57767A patent/GR66576B/el unknown
- 1978-12-01 CH CH1232978A patent/CH646793A5/de not_active IP Right Cessation
- 1978-12-04 LU LU80609A patent/LU80609A1/de unknown
- 1978-12-06 NL NL7811903A patent/NL7811903A/xx not_active Application Discontinuation
- 1978-12-06 NO NO784096A patent/NO784096L/no unknown
- 1978-12-06 AT AT872478A patent/AT360178B/de active
- 1978-12-07 IL IL56152A patent/IL56152A0/xx unknown
- 1978-12-08 GB GB7847795A patent/GB2009927B/en not_active Expired
- 1978-12-08 FI FI783782A patent/FI783782A7/fi unknown
- 1978-12-08 DD DD78209631A patent/DD139903A5/de unknown
- 1978-12-08 AU AU42349/78A patent/AU4234978A/en active Pending
- 1978-12-09 RO RO7895854A patent/RO75333A/fr unknown
- 1978-12-11 ES ES475905A patent/ES475905A1/es not_active Expired
- 1978-12-11 BE BE2057477A patent/BE872651A/xx not_active IP Right Cessation
- 1978-12-11 PT PT68891A patent/PT68891A/pt unknown
- 1978-12-11 ZA ZA00786908A patent/ZA786908B/xx unknown
- 1978-12-11 FR FR7834749A patent/FR2411412A1/fr active Granted
- 1978-12-12 AR AR274770A patent/AR220356A1/es active
- 1978-12-12 JP JP15459078A patent/JPS54100176A/ja active Pending
- 1978-12-12 IT IT30722/78A patent/IT1160323B/it active
- 1978-12-12 PL PL1978211672A patent/PL112675B1/pl unknown
- 1978-12-12 CA CA317,809A patent/CA1129319A/fr not_active Expired
-
1979
- 1979-05-25 ES ES1979243564U patent/ES243564Y/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ATA872478A (de) | 1980-05-15 |
| FR2411412A1 (fr) | 1979-07-06 |
| DE2755363C3 (de) | 1983-12-01 |
| LU80609A1 (de) | 1979-05-16 |
| ZA786908B (en) | 1979-12-27 |
| FR2411412B3 (fr) | 1981-03-27 |
| ES243564Y (es) | 1980-12-16 |
| DK532678A (da) | 1979-06-13 |
| ES243564U (es) | 1980-06-01 |
| DE2755363A1 (de) | 1979-06-13 |
| ES475905A1 (es) | 1979-10-16 |
| PT68891A (en) | 1979-07-24 |
| DE2755363B2 (de) | 1979-12-20 |
| PL112675B1 (en) | 1980-10-31 |
| CA1129319A (fr) | 1982-08-10 |
| BE872651A (nl) | 1979-03-30 |
| SE7812313L (sv) | 1979-06-13 |
| DD139903A5 (de) | 1980-01-23 |
| AU4234978A (en) | 1979-06-21 |
| NL7811903A (nl) | 1979-06-14 |
| GR66576B (fr) | 1981-03-27 |
| SE432157B (sv) | 1984-03-19 |
| AT360178B (de) | 1980-12-29 |
| IL56152A0 (en) | 1979-03-12 |
| IT7830722A0 (it) | 1978-12-12 |
| AR220356A1 (es) | 1980-10-31 |
| FI783782A7 (fi) | 1979-06-13 |
| NO784096L (no) | 1979-06-13 |
| GB2009927A (en) | 1979-06-20 |
| JPS54100176A (en) | 1979-08-07 |
| RO75333A (fr) | 1980-11-30 |
| PL211672A1 (pl) | 1979-09-10 |
| IT1160323B (it) | 1987-03-11 |
| GB2009927B (en) | 1982-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TAGAMI et al. | Leukotactic properties of soluble substances inpsoriasis scale | |
| DE2806146C2 (de) | Tumor-spezifisches Glykoprotein und dessen Verwendung zur Krebsdiagnose beim Menschen | |
| Niebauer et al. | Osmium zinc iodide reactive sites in the epidermal Langerhans cell | |
| DE60201582T2 (de) | Pflaster zur bestimmung des zustands der sensibilisierung eines subjekts für ein allergen | |
| DE3109252C2 (de) | Verfahren und Zusammensetzung zur Bestimmung einzelner Leukozyten durch metachromatische Farbstoffdifferentialabsorption | |
| DE2648458A1 (de) | Reagenz zur diagnose von krebs, dessen herstellung und anwendung | |
| DE2635065A1 (de) | Verfahren zur halbkontinuierlichen behandlung von gesamtblut | |
| Bowers Jr et al. | Numbers of mast cells in the axillary lymph nodes of breast cancer patients | |
| DE3925680C2 (fr) | ||
| DE2755363C3 (de) | Testverfahren zur Diagnose von Malignomen | |
| Wherrett et al. | Erythrocyte glycolipids in Huntington's chorea | |
| WO2001048476A2 (fr) | Extraction de composants biologiques contenus dans des liquides organiques | |
| DE3817762C2 (fr) | ||
| DE2160424C3 (de) | Diagnostisches Gerät zur Gewinnung cytologischer Proben | |
| DE68926121T2 (de) | Präparat von blutzellen spezifischer dichte für den scm-test | |
| Sattar et al. | Rheumatoid‐and osteo‐arthritis: quantitation of ultrastructural features of capillary endothelial cells | |
| DE2441536C3 (de) | Diagnostisches Verfahren | |
| CH662573A5 (de) | Verfahren zur herstellung stark antigener, tumorspezifischer substanzen und deren verwendung als krebsdiagnosemittel. | |
| DE68911305T2 (de) | Das lungenwachstum stimulierende und hemmende faktoren für krebstumorzellen. | |
| Goltz | Das Donath-Landsteiner-Hämolysin. Die Entstehung eines Mythos in der Medizin des 20. Jahrhunderts | |
| DE2606257A1 (de) | Recognine | |
| EP0172841A1 (fr) | Procede de depistage de la proliferation de tumeurs malignes. | |
| AT293611B (de) | Verfahren zur Feststellung von neoplastischem Zellmaterial | |
| DE2546670A1 (de) | Recognine | |
| DE19505795C1 (de) | Proteine enthaltende Komponente aus Thujapflanzen sowie diese enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |